welcome to mjventertainment.com...... Home › Grail Raises $900M in Series B Round Subscribe to Cancer Grail Raises $900M in Series B Round Mar 01, 2017 NEW YORK (GenomeWeb) – Grail has raised $900 million out of a planned $1 billion, in the first close a Series B financing round that was led by Arch Venture Partners and included Johnson and Johnson Innovation as well as Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. Grail plans to use the financing to support ongoing efforts in product development and the validation of its tests for early-stage cancer detection, including its Circulating Cell-free Genome Atlas study and other large-scale clinical trials. The firm said that some of the proceeds were also used to repurchase part of Illumina's stake in the company. Illumina now owns "slightly less than 20 percent" of Grail. The company announced its intention in January to raise $1 billion in the Series B round before the end of the first quarter. Grail CEO Jeff Huber said in a statement that Grail "made tremendous progress in 2016" toward its goal of developing a noninvasive test for early cancer detection. It will continue to leverage "high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science," he said. Filed Under Cancer Business News financing NGS Grail Illumina We recommend Grail Seeks to Raise $1B in Series B; Illumina's Stake to Fall Below 20 Percent 360Dx, 2017 Paradigm Diagnostics Raises Additional $3M in Series B Round 360Dx, 2017 Atlas Genetics Raises $35M in Series D Fundraising 360Dx, 2017 Intuity Medical Raises Additional $15M in Series 3 Financing 360Dx, 2017 UK Genomics Firm Congenica Raises $10M 360Dx, 2017 Genalyte Raises $36M in Funding 360Dx, 2016 Powered by TrendMD Breaking News Roche Q1 Diagnostics Revenues Up 6 Percent Clovis, Myriad Genetics Working to Meet Post-Market Study Commitment for PARP Inhibitor Exact Sciences Q1 Revenues Triple Meridian Bioscience's Q2 Revenues Up 6 Percent Fulgent Genetics Forms JV in China Synlab to Offer Counsyl's Inherited Disease Screening Test in Europe, Latin America Featured White Papers By NanoString Nanostring Profiling in Immuno-Oncology By Myriad RBM Quality Systems for Multiplex Immunoassay Testing Services for Clinical Trials May 04 Featured Webinar Liquid Biopsies for Improved Recurrence Monitoring in Colorectal Cancer Sponsored by Qiagen This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer. What's Popular? In Cancer US Task Force Changes Guidelines for Prostate Cancer Screening Clovis, Myriad Genetics Working to Meet Post-Market Study Commitment for PARP Inhibitor Almac Diagnostics, EORTC Collaborate to Establish Molecular Profiles for Cancer Patients Urine DNA Test Shows Potential for Early Bladder Cancer Detection, Danish Team Reports at AMP Global MDNA Inks South Korean Distribution Deal for Prostate Cancer Test Sponsorships